Reference health
Synergistic effect of ibrutinib and CD19 CAR‐T cells on Raji cells in vivo and in vitro
32/32 checkable references clean · checked 2026-07-24
Every reference with a DOI in the deposited reference list resolved to a known work in Crossref or DataCite at the dated check, and none carried a retraction, withdrawal, or removal notice.
The 32 checked references that resolve
resolves10.1038/leu.2016.181
Ibrutinib downregulates a subset of miRNA leading to upregulation of tumor suppressors and inhibition of cell proliferation in chronic lymphocytic leukemia
resolves10.1182/blood-2013-02-482125
Egress of CD19+CD5+ cells into peripheral blood following treatment with the Bruton tyrosine kinase inhibitor ibrutinib in mantle cell lymphoma patients
resolves10.1038/leu.2013.358
BTK inhibition targets in vivo CLL proliferation through its effects on B-cell receptor signaling activity
resolves10.1182/blood-2011-10-386417
The Bruton tyrosine kinase inhibitor PCI-32765 thwarts chronic lymphocytic leukemia cell survival and tissue homing in vitro and in vivo
resolves10.1128/MCB.00247-13
Dual Phosphorylation of Btk by Akt/Protein Kinase B Provides Docking for 14-3-3ζ, Regulates Shuttling, and Attenuates both Tonic and Induced Signaling in B Cells
resolves10.1200/JCO.2013.53.1046
Bruton's Tyrosine Kinase: From X-Linked Agammaglobulinemia Toward Targeted Therapy for B-Cell Malignancies
resolves10.1200/JCO.2012.42.7906
Bruton Tyrosine Kinase Inhibitor Ibrutinib (PCI-32765) Has Significant Activity in Patients With Relapsed/Refractory B-Cell Malignancies
resolves10.1182/blood-2014-02-548610
Ibrutinib inhibits BCR and NF-κB signaling and reduces tumor proliferation in tissue-resident cells of patients with CLL
resolves10.1056/NEJMoa1306220
Targeting BTK with Ibrutinib in Relapsed or Refractory Mantle-Cell Lymphoma
resolves10.1038/s41375-018-0023-2
Ibrutinib versus temsirolimus: 3-year follow-up of patients with previously treated mantle cell lymphoma from the phase 3, international, randomized, open-label RAY study
resolves10.1038/leu.2016.157
Clinical response to ibrutinib is accompanied by normalization of the T-cell environment in CLL-related autoimmune cytopenia
resolves10.1182/blood-2014-09-603670
Outcomes of patients with chronic lymphocytic leukemia after discontinuing ibrutinib
resolves10.1001/jamaoncol.2014.218
Etiology of Ibrutinib Therapy Discontinuation and Outcomes in Patients With Chronic Lymphocytic Leukemia
resolves10.1056/NEJMoa1707447
Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
resolves10.1056/NEJMoa1804980
Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma
resolves10.1056/NEJMoa1709866
Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia
resolves10.1056/NEJMoa1103849
Chimeric Antigen Receptor–Modified T Cells in Chronic Lymphoid Leukemia
resolves10.1126/scitranslmed.aac5415
Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia
resolves10.1200/JCO.2017.72.8519
Durable Molecular Remissions in Chronic Lymphocytic Leukemia Treated With CD19-Specific Chimeric Antigen Receptor–Modified T Cells After Failure of Ibrutinib
resolves10.1158/1078-0432.CCR-15-1527
The Addition of the BTK Inhibitor Ibrutinib to Anti-CD19 Chimeric Antigen Receptor T Cells (CART19) Improves Responses against Mantle Cell Lymphoma
resolves10.1186/s40425-019-0686-x
State-of-the-art for CAR T-cell therapy for chronic lymphocytic leukemia in 2019
resolves10.1038/s41591-018-0010-1
Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia
resolves10.1182/blood-2017-06-786129
Cellular kinetics of CTL019 in relapsed/refractory B-cell acute lymphoblastic leukemia and chronic lymphocytic leukemia
resolves10.1182/blood-2015-11-679134
Ibrutinib enhances chimeric antigen receptor T-cell engraftment and efficacy in leukemia
resolves10.1182/blood-2012-08-452607
Coming full circle: 70 years of chronic lymphocytic leukemia cell redistribution, from glucocorticoids to inhibitors of B-cell receptor signaling
resolves10.1016/S1470-2045(14)70335-3
Safety and activity of ibrutinib plus rituximab for patients with high-risk chronic lymphocytic leukaemia: a single-arm, phase 2 study
resolves10.1038/leu.2017.304
Ibrutinib modulates the immunosuppressive CLL microenvironment through STAT3-mediated suppression of regulatory B-cell function and inhibition of the PD-1/PD-L1 pathway
resolves10.1182/blood-2013-06-507947
Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1-selective pressure in T lymphocytes
resolves10.4049/jimmunol.1601190
Ibrutinib Therapy Increases T Cell Repertoire Diversity in Patients with Chronic Lymphocytic Leukemia
What this badge says. CiteStamped means the CHECKABLE references of this
work were clean at the dated check: each resolved to a known work in a public registry, and none
carried a retraction notice at that time. It says nothing about the quality, findings,
or importance of the work itself, and nothing about references deposited without a DOI.
checked 2026-07-24 — re-checked daily as this page is visited; titles and statuses come from Crossref and DataCite and are not part of the signed record
Embed this badge
Both snippets point at the live badge image and link back to this page. The badge re-renders from the daily check, so an embed never goes stale by more than a day of visits.
<a href="https://citestamp.com/citestamped/10.1111/cas.14638"><img src="https://citestamp.com/citestamped/10.1111/cas.14638/badge.svg" alt="CiteStamped reference-health badge" width="460" height="64"></a>
[](https://citestamp.com/citestamped/10.1111/cas.14638)